Has tenapanor been officially launched in the country?

Tenapanor (tenapanor) has been officially launched in China and has been included in the scope of medical insurance reimbursement, but it may not be implemented until 2026, which means that patients need to purchase it at their own expense when using it, and the cost is relatively high. Since the official selling price has not yet been announced in China, patients need to consult the hospital pharmacy for specific prices in order to obtain the most accurate drug purchasing information and purchasing channels. Patients should fully understand the indications and potential risks of the drug before use, and avoid using it randomly or adjusting the dosage on their own.

Tenapanol mainly works by inhibiting intestinal sodium and hydrogen exchange protein (NHE3), thereby reducing sodium absorption and regulating water balance. It is suitable for the adjuvant treatment of chronic kidney disease with constipation or hyperphosphatemia. Its targeting effect makes the efficacy more significant and can improve the patient's quality of life to a certain extent. Clinical studies have shown that the drug can effectively relieve constipation symptoms and help control electrolyte imbalances associated with kidney disease.

In overseas markets, Tenapano’s original drug is more expensive, with a box selling for more than three thousand US dollars. This reflects its research and development costs and clinical value as a new targeted drug. Overseas drug purchases must be through formal channels to ensure drug quality and safety, and to avoid problems of counterfeit drugs or uncertain efficacy caused by purchasing through informal channels.

Generally speaking, when domestic patients use Tenapano, they should obtain the drug through regular hospital and pharmacy channels, and at the same time develop an individualized treatment plan based on the guidance of a doctor. Although medical insurance has just covered it, the clinical value of drugs is still significant. However, before treatment, you should fully evaluate your own condition, drug safety, and financial affordability to ensure that you can obtain curative effects while reducing potential risks, and achieve safe and effective treatment.

Reference materials:https://www.ema.europa.eu/en/homepage